Table III.
Alteration of M.tb-induced Genes by DEP and LPS.
|
M.tb-induced genes altered by DEP pre- stimulation (relative to M.tb) |
M.tb-induced genes altered by LPS pre- stimulation (relative to M.tb) |
M.tb-induced genes not altered by DEP pre-stimulation (relative to M.tb) |
M.tb-induced genes not altered by LPS pre-stimulation (relative to M.tb) |
|---|---|---|---|
| CCL5 ↓ | CCL7 ↓ | CCL2 | CCL2 |
| CCR4 ↓ | CLEC4E ↑ | CCL7 | CCL5 |
| CD86 ↑ | CSF2 ↓ | CD180 | CCR4 |
| CEBPB ↑ | HAVCR2 ↓ | CD40LG | CD180 |
| CSF3 ↓ | IL1R1 ↑ | CLEC4E | CD40LG |
| CTLA4 ↓ | IL12B ↓ | CSF2 | CD86 |
| CXCR3 ↓ | IL12RB2 ↓ | ELK1 | CEBPB |
| FOS ↑ | INHBA ↓ | HAVCR2 | CSF3 |
| GATA3 ↓ | IRF4 ↓ | IL10 | CTLA4 |
| ICOS ↓ | TBX21 ↓ | IL12RB2 | CXCR3 |
| IFNA1 ↓ | TNF ↓ | IL13 | ELK1 |
| IGSF6 ↑ | TNFRSF9 ↓ | IL1R2 | FOS |
| IL13RA ↑ | IL23A | GATA3 | |
| IL18 ↑ | CD80 ↓ | IL8 | ICOS |
| IL1A ↓ | CXCL10 ↓ | INHBA | IFNA1 |
| IL5 ↓ | EIF2AK2 ↓ | IRAK2 | IGSF6 |
| IL6 ↓ | FASLG ↓ | IRF1 | IL10 |
| IL7 ↓ | IFNB1 ↓ | IRF4 | IL13 |
| NFkB1A ↓ | IFNG ↓ | JUN | IL13RA |
| PTGS2 ↓ | IL18R1 ↓ | LTA | IL18 |
| SOCS1 ↓ | IL2RA ↓ | MAP4K4 | IL1A |
| SSP1 ↑ | LAG3 ↓ | NFKB1 | IL23A |
| TLR10 ↓ | TLR3 ↓ | RIPK2 | IL6 |
| TLR4 ↓ | SIGIRR | IL7 | |
| TLR7 ↓ | SOCS2 | IL8 | |
| TNFSF4 ↓ | STAT4 | IRAK2 | |
| TBX21 | IRF1 | ||
| CD80 ↓ | TLR1 | JUN | |
| CXCL10 ↓ | TLR5 | LTA | |
| EIF2AK2 ↓ | TLR8 | MAP4K4 | |
| FASLG ↓ | IL12B | NFKB1 | |
| IFNB1 ↓ | TNF | NFKB1A | |
| IFNG ↓ | TNFRSF8 | PTGS2 | |
| IL18R1 ↓ | TNFRSF9 | RIPK2 | |
| IL2RA ↓ | UBE2V1 | SIGIRR | |
| LAG3 ↓ | SOCS1 | ||
| TLR3 ↓ | SOCS2 | ||
| SSP1 | |||
| STAT4 | |||
| TLR1 | |||
| TLR10 | |||
| TLR4 | |||
| TLR5 | |||
| TLR7 | |||
| TLR8 | |||
| IL5 | |||
| TNFRSF8 | |||
| TNFSF4 | |||
| UBE2V1 | |||
The mRNA levels of PBMC stimulated with M.tb following DEP or LPS pre-stimulation were compared with that of PBMC stimulated with M.tb alone. Increased or decreased (≥ 2-fold, p ≤ 0.01) mRNA expression levels relative to mRNA expression levels of M.tb-stimulated PBMC (set as 0-value) are shown. mRNAs altered by both DEP and LPS (columns 1 and 2) are underlined. Abbreviations not shown in legend to Table 2: CLEC4E C-type lectin domain family 4, member E, HAVCR2 hepatitis A virus cellular receptor 2, IL12B interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40), IL12B2 interleukin 12 receptor beta 2, INHBA inhibin beta A, IRF4 interferon regulatory factor 4, TBX21 T-box 21, TNF tumor necrosis factor (TNF superfamily, member 2), TNFRSF9 tumor necrosis factor receptor superfamily member 9, CCL2 Chemokine (C-C motif) ligand 2, CD180 CD80 molecule, CD40LG CD40 ligand, ELK1 ELK1, member of ETS oncogene family, IL10 interleukin 10, IL23A interleukin 23, alpha subunit p19, IL8 interleukin 8, IRAK2 interleukin-1 receptor-associated kinase 2, IRF1 interferon regulatory actor 1, JUN jun oncogene, LTA lymphotoxin alpha (TNF superfamily, member 1), MAP4K4 mitogen-activated protein kinase 4, NFkB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, RIPK2 receptor-interacting serine-threonine kinase 2, SIGIRR single immunoglobulin and toll-interleukin 1 receptor (TIR) domain, SOCS2 suppressor of cytokine signaling 2, STAT4 signal transducer and activator of transcription 4, TLR1 toll-like receptor 1, TLR8 toll-like receptor 8, TNFSF8 tumor necrosis factor ligand superfamily member 8, UBE2V1 ubiquitin-conjugating enzyme E2 variant 1, IL13 interleukin 13, IL13RA interleukin 13 receptor alpha 1, TLR8 toll-like receptor 8.